Published in Aging and Elder Health Week, August 21st, 2005
The trial is a randomized, double-blind, parallel group design, comparing three doses of cetilistat with placebo and with orlistat (Roche's Xenical). Patients are being treated for 12 weeks with 4 weeks follow up, the primary endpoint being weight loss. In addition, a number of other parameters associated with obesity, including cholesterol and markers for diabetes will be measured. An additional objective of the study is to determine the safety and tolerability profile of cetilistat in these patients, compared to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Aging and Elder Health Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.